Browse the 369 posters accepted to this year's symposium. Search by author name, by keyword in the title, or narrow to a category. Click any keyword chip on a result to pivot to a related search.
-
PR 8.5
Polyp Detection After Extended Surveillance Intervals: Outcomes in Patients With Low-Risk Tubular Adenomas
-
PR 8.33
Clinical Outcomes of Radioactive Iodine Therapy in Patients with Negative Pre-therapy I-131 Scans After Redifferentiation Therapy for RAI-Refractory Thyroid Cancer
-
60 8.03
Prognostic Impact of Pre-Transplant Measurable Residual Disease in Acute Myeloid Leukemia: A Bayesian Meta-Analysis of Contemporary Allogeneic Hematopoietic Cell Transplantation Cohorts
-
33 8.0
Examining the smoking paradox: A descriptive analysis of prior and current smoking behaviors by race among patients enrolled in a smoking cessation trial at MedStar Health
-
48 8.0
Immune-mediated toxicities (irAEs) in immune checkpoint inhibitor (ICI) therapy in various combinations: a real-world sample
-
61 8.0
Cutting It Close: Navigating Surgical and Radiation Management for Borderline Margins in DCIS with DCISionRT
-
62 7.83
Implementation of Electronic Medical Record Prompts Enhances Clinical Trial Access and Equity in Gynecologic Oncology: a Reach, Effectiveness, Adoption, Implementation, and Maintenance analysis
-
51 7.73
Distinct IL-1/VEGF-Dominant Phenotype in IL-6-Refractory Multicentric Castleman Disease: A Pooled Matched Analysis of Anakinra versus IL-6 Blockade
-
43 7.57
Socioeconomic and Demographic Disparities in Chemotherapy Use After Metastasectomy for Stage IV Rectal Cancer
-
44 7.5
Real-World Assessment of the Impact of Neighborhood Vulnerabilities on Prostate Cancer Outcomes in the Medstar Health Network
-
50 7.3
-
54 7.17
Therapeutic Architecture Rather Than Population Differences Drives Front-Line Outcomes in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Comparison-Specific Pooled Analysis of Rituximab-Era Cohorts
-
31 6.9
Metabolic comorbidity and cognition among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study
-
58 6.87
Predicting Complete Treatment Response in Young-Onset Rectal Cancer: Uncovering Clinicodemographic Factors
-
36 6.73
-
PR 6.6
Cures of Peritoneal Appendiceal Cancer Xenografts Using GPA33-SADA Pretargeted Alpha and Beta Radiopharmaceutical Therapy
-
45 6.58
Real world association between the Androgen Receptor gene polymorphisms (CAG repeats) and aggressiveness of prostate cancer at diagnosis in the Medstar Health Network
-
56 6.57
Racial Disparities in Prostate Cancer Tumor Profiles: Real-World Evidence from the MedStar Health System
-
65 6.57
Underutilization of Germline Testing in MLH1/PMS2-Deficient Colorectal Cancer: Identifying Barriers to Lynch Syndrome Evaluation
-
59 6.5
POST-CART: Primary Care Oversight and Survivorship After CAR-T — A Pilot Cross-Sectional Survey
-
29 6.4
-
52 6.4
Steroid Non-Response Predicts IL-6 Blockade Failure and Defines a Non-IL-6-Dominant Inflammatory Subset in TAFRO Syndrome: A Pooled Patient-Level Analysis
-
55 6.4
Differential Toxicity Patterns with Bispecific Antibody Monotherapy and Daratumumab-Based Combinations in Multiple Myeloma - A Pooled Analysis
-
53 6.33
Assessing Area Deprivation Index and Social Vulnerability Index as Measures of Neighborhood Disadvantage in Prostate Cancer Disparities
-
30 6.25
Utilizing Rapid & In-Depth Qualitative Analysis to Understand Multilevel Barriers to Lung Cancer Screening
-
37 6.15
Sociodemographic predictors of palliative care utilization across the MedStar Health system
-
47 6.1
Frailty as a Predictor of Outcomes and Treatment Selection in Older Adults with Diffuse Large B-Cell Lymphoma: Real-World Evidence from a Community-Based Cohort
-
28 5.93
Harnessing Natural Killer Cells to Overcome Immune Evasion in Triple-Negative Breast Cancer
-
63 5.85
Simplified Assessment of Outcome for Treatment of Peritoneal Metastases From Colorectal Cancer
-
46 5.8
Clinical characterization and association with autoimmunity in immune checkpoint inhibitor (ICI)-mediated thyroid dysfunction in a real-world sample
-
40 5.67
EmpowHERing HPV Research Among Urban Native American Women: A Community-Engaged Mixed-Methods Study
-
34 5.65
Retrospective Data Analysis of Lung Cancer Screening Completion Rates as Predicted by Neighborhood Disadvantage Among Primary Care Patients at MedStar Health
-
39 5.65
Have the prognostic factors for glioblastoma changed with the adoption of the WHO 2021 definition of Glioblastoma? A single institutional analysis of patients receiving standard radiation and temozolomide.
-
42 5.53
Impact of the Rectal Cancer Center of Excellence Designation and Protocol Implementation on Patient Outcomes
-
38 5.5
The Association Between Time Since Cancer Diagnosis and Tobacco Treatment Reach
-
57 5.5
Artificial Intelligence Driven Analysis of Tumor Growth in Multiple Endocrine Neoplasia 2-Associated Pheochromocytoma: Predicting Surgical Windows
-
41 4.9
A wolf in sheep's clothing: molecular glioblastoma
-
64 4.9
Clinical Predictors of Remission in TAFRO Syndrome: A Pooled Meta Analysis of 70 Published Cases
-
32 4.77
Perceptions of Engagement and Effectiveness of Continuous Glucose Monitoring App Features Among Adults With Type 1 and Type 2 Diabetes
-
49 4.75
Predicting immune-related adverse events (irAEs) with large language model (LLM) embeddings
-
70 4.73
Spontaneous Tumor Lysis Syndrome in Solid Tumors: Fatal Presentation of Metastatic Urothelial Carcinoma
-
35 4.67
Obesity associated Estrogen:NFκB cooperation drives NK cell impairment in Estrogen Receptor Positive Breast Cancer
-
71 4.5
A Novel Drug-Induced Sarcoidosis-Like Reaction Associated with Paclitaxel in a Patient with Breast Cancer
-
68 4.43
A rare case of gastric metastatic Melanoma
-
67 4.27
A Rare Case of Pediatric Fibrolamellar Hepatocellular Carcinoma Presenting With Paraneoplastic Myasthenia Gravis and a Unique Morphologic Variation
-
69 4.2
Infiltration Concealed by Inflammation: Linitis Plastica Mimicking IBD
-
66 4.15
Periorbital bullae mimicking SJS/TEN during concomitant chemoradiation for glioblastoma: A case report and risk-mitigation strategy
-
72 4.1